X-ZELL featured in German life science magazine Laborjournal
Freiburg, April 2020 – X-ZELL has been featured in the April edition of Laborjournal, one of Germany’s leading life science publications.
The extensive company profile, penned by science journalist Dr Sigrid März, outlines X-ZELL’s rapid ascent from a small Bangkok laboratory into one of the most exciting cancer screening start-ups in the world – with a special focus on the mind and motivation of company founder, Dr Sebastian Bhakdi.
Referencing Bhakid’s dual heritage, März observes a distinct down-to-earthness in X-ZELL’s ambitious chief executive – making for an “extraordinary” amalgamation of global aspiration, Thailand’s famed can-do attitude and German dependability.
“First we make sure that what we do is working and scientifically sound – then we go from there. X-ZELL is a Thai start-up with Silicon Valley experience and a German Mittelstand approach,” Bhakdi is quoted, referring to Germany’s world-renowned SME sector.
März goes on to dissect the company’s corporate and scientific genesis, detailing how X-ZELL’s patented rare cell detection technology could take pathology into the digital age and shake up early cancer detection.
In a world-first, Laborjournal also reveals why the word ‘cell’ in X-ZELL is spelled with a ‘z’.
“I am half German and it will always be part of my identity,” Dr Sebastian Bhakdi shared. “Spelling X-ZELL with a ‘z’ is the perfect representation of my personal heritage and X-ZELL’s unique DNA.”
Find the full (German language) article here: http://www.laborjournal-archiv.de/epaper/LJ_20_04/46/index.html
Head of Strategy, Marketing & Communications
+66 6 2197 8788
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines for successfully isolating and visualising tumour-associated Circulating Endothelial Cells (tCEC) from the blood of high-risk prostate cancer patients. Long considered undetectable in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancers early, when they can be cured – in turn avoiding more than 70 per cent of unnecessary interventions and saving billions to health systems worldwide. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.
© 2023 X-ZELL INC